AbbVie Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (88)

Latest Posts

About This Stock More About This Stock
Biopharmaceuticals Portfolio In A Biotech Bull Market
Article By: Rod Raynovich
Tuesday, September 5, 2017 11:08 PM EDT
Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July 2015 bubble highs but supported by good earnings fundamentals, strong technicals and potentially a seasonal strong Q4.
In this article: BMY, RHHBY, IBB, QQQ, AMGN, BIIB, GILD, XBI, ABBV, KITE, BLUE, FMI
Read
Investors Expecting Growth From Large Caps And M&A From Mid-Caps
Article By: Rod Raynovich
Tuesday, August 15, 2017 9:37 PM EDT
Biotech stocks in general have recovered from last week’s sell-off and remain in a monthly trend up despite a topping pattern from July. Despite weak seasonality and lack of M&A the sector is holding lows with good volume.
In this article: BMY, IBB, AMGN, CELG, GILD, XBI, XLV, ABBV, BLUE, FMI
Read
5 Great Stocks With Steady Dividends
Article By: Modest Money
Wednesday, August 9, 2017 11:33 AM EDT
These stocks are for investors who want their investments to work for them while they go and play.
In this article: SO, ABBV, MAIN, T, WPC
Read
Large Cap Biopharma Earnings Boost Stocks: Update Tuesday, Aug 1
Article By: Rod Raynovich
Tuesday, August 1, 2017 10:42 PM EDT
Stocks were broadly higher in July after financial reports. Now that earnings are in, track technicals and potential clinical catalysts for August/September which can be weak seasonally.
In this article: BMY, MBI, MRK, RHHBY, ALXN, IBB, REGN, AMGN, CELG, GILD, XBI, ABBV, BLUE, FMI, FBIOX, FBT
Read
4 Drug Stocks In Focus This World Hepatitis Day
Article By: Arpita Dutt
Friday, July 28, 2017 10:45 AM EDT
The HCV market will continue to face challenges as more treatments enter the market resulting in increased competition and additional pricing pressure. In fact, HCV drugs have faced immense scrutiny due to their high prices.
In this article: GILD, MRK, ABBV, ENTA
Read

PARTNER HEADLINES

Latest Tweets for $ABBV

No tweets yet!

$ABBV

AbbVie Inc. Increases Humira Prices, Receives FDA Approval For New Drug
Bruce Powers 1/23/2017 6:21:09 PM

Excited to hear the #FDA approved #IMBRUVICA. Should bode very well for $ABBV. And I think it's 8% price hike of #Humira is reasonable (though I realize those taking the drug may disagree).

1 to 1 of 1 comments